Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab

Bibliographic Details
Main Authors: Yuri Vladimirovich Muravyev, G I Gridina, D E Karateev
Format: Article
Language:Russian
Published: IMA PRESS LLC 2013-06-01
Series:Научно-практическая ревматология
Online Access:https://rsp.mediar-press.net/rsp/article/view/1663
_version_ 1826556102491242496
author Yuri Vladimirovich Muravyev
G I Gridina
D E Karateev
author_facet Yuri Vladimirovich Muravyev
G I Gridina
D E Karateev
author_sort Yuri Vladimirovich Muravyev
collection DOAJ
first_indexed 2024-04-09T22:25:39Z
format Article
id doaj.art-dd025cb4f54a43f08d1cedb731203067
institution Directory Open Access Journal
issn 1995-4484
1995-4492
language Russian
last_indexed 2025-03-14T08:07:22Z
publishDate 2013-06-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj.art-dd025cb4f54a43f08d1cedb7312030672025-03-02T13:23:38ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922013-06-0151335435610.14412/1995-4484-2013-15141600Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumabYuri Vladimirovich MuravyevG I GridinaD E Karateevhttps://rsp.mediar-press.net/rsp/article/view/1663
spellingShingle Yuri Vladimirovich Muravyev
G I Gridina
D E Karateev
Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
Научно-практическая ревматология
title Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
title_full Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
title_fullStr Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
title_full_unstemmed Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
title_short Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
title_sort thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor inhibitor adalimumab
url https://rsp.mediar-press.net/rsp/article/view/1663
work_keys_str_mv AT yurivladimirovichmuravyev thromboembolismisanunexpectedpoorresponseresultingfromtheuseofthetumornecrosisfactorinhibitoradalimumab
AT gigridina thromboembolismisanunexpectedpoorresponseresultingfromtheuseofthetumornecrosisfactorinhibitoradalimumab
AT dekarateev thromboembolismisanunexpectedpoorresponseresultingfromtheuseofthetumornecrosisfactorinhibitoradalimumab